AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4

Emsita-M 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Emcure Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Emsita-M 50/500 Tablet

DiabetaComb 50/500 tablets combine two medications to manage elevated blood glucose in patients with type 2 diabetes. This dual action helps prevent serious diabetic complications like renal impairment and vision loss, potentially lowering heart attack and stroke risk. DiabetaComb 50/500 may be used as monotherapy or in conjunction with other antidiabetic agents. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is individualized based on your health status, blood sugar readings, and concurrent medications. Consuming the tablet with food minimizes gastrointestinal upset. Consistent daily dosing at the same time maximizes efficacy; discontinuation should only occur under physician guidance. Adherence to your prescribed diet and exercise regimen is crucial. Lifestyle choices significantly impact diabetes management. Common adverse events include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential side effect, especially with concomitant insulin or sulfonylurea use; learn to recognize and manage this complication. This medication is not universally appropriate. Inform your doctor of any prior kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals should seek medical advice before use. Drug interactions are possible; disclose all medications to your physician to ensure safety. Alcohol should be minimized due to its hypoglycemic effects. Your doctor will monitor your renal function and blood glucose levels throughout treatment.

Uses of Emsita-M 50/500 Tablet

Managing type 2 diabetes

Major Benefits of Emsita-M 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Emsita-M 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. It should be administered with a meal.

Common Side effects of Emsita-M 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Emsita-M 50/500 Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the Emsita-M 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. It should be taken with a meal.

How Emsita-M 50/500 Tablet works:

Emsita-M 50/500 tablets combine sitagliptin and metformin to manage blood sugar levels. Sitagliptin enhances insulin production by the pancreas, improves the body's insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and boosts insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol while taking Emsita-M 50/500 Tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Emsita-M 50/500 Tablet during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the potential advantages against the risks before prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Emsita-M 50/500 Tablet while breastfeeding is likely inadvisable. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Emsita-M 50/500 Tablets cautiously, potentially requiring dosage modification. Consult your physician. Emsita-M 50/500 Tablets are contraindicated in patients with severe kidney disease. Regular monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

The use of Emsita-M 50/500 tablets is likely inadvisable for individuals with hepatic impairment and should be avoided. Medical advice is recommended.

What if you forget to take Emsita-M 50/500 Tablet :

Should you forget to take your Emsita-M 50/500 Tablet, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosage regimen. Avoid taking a double dose.

Facts to Know About Emsita-M 50/500 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Emsita-M 50/500 Tablet

Emsita-M 50/500 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged Emsita-M 50/500 Tablet use can induce vitamin B12 deficiency by hindering its stomach absorption. This deficiency, if left unaddressed, may lead to anemia, neurological issues such as numbness, tingling in extremities, weakness, urinary dysfunction, cognitive changes, and ataxia. To mitigate these risks, supplemental yearly vitamin B12 intake is recommended by some researchers.
Emsita-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Emsita-M 50/500 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Emsita-M 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Emsita-M 50/500 (containing metformin) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA). This rare side effect necessitates avoiding metformin in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Emsita-M 50/500 tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood glucose control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Emsita-M 50/500 Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Emsita-M 50/500 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in individuals with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Emsita-M 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Emsita-M 50/500 Tablet can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If these symptoms occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Emsita-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifested as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes (including impaired balance). To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the packaging. Discard any unused medication; keep it out of reach of children, pets, and others.
Emsita-M 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. It helps control blood sugar when used with diet and exercise. Metformin reduces liver glucose production and improves insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Emsita-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Emsita-M 50/500 Tablets are contraindicated in patients with hypersensitivity to any component or excipient. This medication should also be avoided in those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Emsita-M 50/500 tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Emsita-M 50/500 (containing metformin) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also called MALA, Metformin-Associated Lactic Acidosis). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Emsita-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, neurological issues like numbness, tingling in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Emsita-M 50/500 Tablet
142
MRP 165
13% off